Key Drivers
- Gross Margin
- Negative Equity
- High Leverage
AIAI Summary
ATEC should now be viewed less as a pure growth medtech and more as a high-risk turnaround, because steady revenue growth and 70%+ gross margins are being outweighed by heavy leverage, negative equity, and legal overhang; unless management quickly converts that top-line momentum into operating leverage and tighter expense control, the equity story remains fragile.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Negative Equity
- •High Leverage
ATEC generates strong gross margins and some operating cash, but persistent losses, negative equity, heavy debt, and a sales-based valuation keep the financial profile fragile.
Price Behavior
Key Price Behavior Insights:
- •Broken support
- •Capped rebounds
- •Base attempt
ATEC remains in a clear downtrend over the last month, with failed rebounds below $10 and a likely support test near $6.99–$7.00, though oversold conditions leave room for a short-term bounce.
Sharp gap down on 2026-05-06 that failed to reclaim the prior $10 area
Sentiment & News
Key News Insights:
- •Strong Q1 results
- •Sharp stock selloff
- •Legal scrutiny rising
ATEC reported solid Q1 results with $192M revenue and break-even EPS, but the stock sold off sharply as investors weighed volatility and multiple securities-law investigations tied to its disclosures.
The earnings beat is being overshadowed by litigation risk and negative sentiment, which may pressure the stock until investigations and disclosure concerns are resolved
Similar Companies in Healthcare
Other companies in the same sector with AI ratings